Journal of Community Nursing - page 57

JCN
2013,Vol 27, No 4
57
WOUND CARE
Figure 8.
Bar chart showing change in heel
LEP:TP ratio over 28-day period in
patient SH.
Figure 9.
(From left to right) a. Normal uninjured skin (right heel); b. injured skin (right heel), day 0; c. injured skin (right heel) treated with
KerraPro Heel, day 28.
Figure 10.
(From left to right) a. Normal uninjured skin (left heel); b. injured skin (left heel), day 0; c. injured skin (left heel) treated with KerraPro
Heel, day 28.
Patient 5: EW
Patient EW had an elevated number
of red pixels at day 0, indicating the
presence of oedema (
Figure 15b
).
After four weeks of treatment with
an unspecified pad, the skin
remained oedematous (
Figure 15c
).
Conversely, on the left heel (
Figure
16b, c
) which was treated with
KerraPro Heel, the odematous
tissue seen on day 0 resolved after
four weeks. LEP:TP ratios (
Figure
17
) revealed that oedema was
similar in both heels at day 0.
However, by the end of the
evaluation, the heel treated with
KerraPro Heel had seen a dramatic
reduction in oedema levels to
below the normal tissue level,
whereas the right heel showed no
reduction and a slight worsening of
oedema over time.
CONCLUSIONS
The interim results of this
15-patient evaluation into the
effectiveness of KerraPro Heel
pressure-reducing pads at
preventing deterioration and
promoting improvement in skin
condition of patients with category
1 pressure damage to the heel,
indicate that KerraPro Heel
pressure reducing pads effectively
prevent pressure damage, while
having a positive effect on
tissue recovery.
This was demonstrated by the
decrease in oedematous tissue over
time and a restoration to normal
uninjured skin. LEP:TP ratios for
the five patients confirmed that
KerraPro Heel pressure-reducing
pad was more effective at resolving
oedema over the course of the four-
week evaluation, compared with
the usual treatment given
(Aderma, n=1; No pad, n=1;
Unnamed pad, n=1; KerraPro,
n=2); findings which were reflected
in the comparative ultrasound
scans (
Figures 3–17
).
The use of ultrasound was
helpful in detecting the sub-
clinical skin changes that occur
in the earliest phases of pressure
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Normal
No Pad
Kerrapro
Time 0
4 weeks
1...,47,48,49,50,51,52,53,54,55,56 58,59,60,61,62,63,64,65,66,67,...116